What is Peritoneal Carcinomatosis?
Peritoneal Carcinomatosis, in it's relationship to Pseudomyxoma Peritonei, is broad description in which multiple tumors develop in, and line the peritoneal abdominal cavity and linings. These tumors may be difficult to completely remove surgically and may recur despite conventional systemic chemotherapy. HIPEC may be an appropriate treatment for this condition.
The description of Peritoneal Carcinomatosis includes a variety of tumors that present with extensive metastasis throughout the peritoneal cavity. This description is used in conjunction with cancers and conditions of appendix, colon, gall bladder, ovaries, mesothelioma, pancreas, Pseudomyxoma Peritonei, rectal, sarcomas, small bowel, and stomach. When tumor develops from the peritoneum, it is referred to as Primary Peritoneal Surface Malignancy.
Diagnosis
The diagnosis of Peritoneal Mucinous Carcinomatosis indicates the presence of mucin accompanied by abundant malignant epithelium, high-grade atypia (Ronnett et al, 1995). Mucinous Carcinomatosis indicates a more challenging prognosis relative to the more common pattern of Disseminated Peritoneal Adenomucinosis aka DPAM.
Diagnosis may be suspected based on physical symptoms, CT scans, and tumor marker tests. However, the actual diagnosis is confirmed by pathologists after examination of tissue and/or mucin or fluid samples.
Refer to our diagnostics page for detailed information describing laboratory and imaging testing.
Symptoms
Symptoms of Peritoneal Carcinomatosis may initially be detected by appearing on as a diffused thickening of the peritoneum on a CT scan. The appearance of ascites refers to the accumulation of fluid within the peritoneal cavity and may occur for a variety of conditions including post operative inflammation or to cancer. For Appendix Cancer and Psuedomyxoma Peritonei patients, ascites may appear as a rapid increase in fluid within in abdomen. This condition requires immediate medical attention.
Treatment*
Peritoneal Carcinomatosis Treatment* generally includes specific surgery, with or without HIPEC or systemic chemotherapy. Your specialist can help you determine the best course of treatment for Peritoneal Carcinomatosis.
An international listing of Surgeons & Specialists providing Peritoneal Carcinomatosis treatment is listed on this website for your convenience.
HIPEC or Hyperthermic Intraperitoneal Chemotherapy, for the Peritoneal Carcinomatosis treatment, may be administered if complete tumor debulking is accomplished through cytoreductive surgery. HIPEC includes the infusion of the abdominal cavity with a specific chemotherapy, heated to approximately 40 degrees Celsius for a period of approximately 90 minutes. The purpose of the HIPEC is to attempt to kill any tumor cells which were not removed during the actual surgery process.
Learn more about HIPEC
How is it administered?
Is it effective for the treatment of Pseudomyxoma Peritonei, Appendix Cancer, Peritoneal Carcinomatosis
Successful Survivorship
View "Pal Profiles" and photos of patients living successfully following the diagnosis of Peritoneal Carcinomatosis.
You may also refer to the following websites for information regarding treatment for Peritoneal Carcinomatosis:
Peritoneal Carcinomatosis Definitions
Peritoneal Carcinomatosis Synonyms
Source: Quest Diagnostics
Peritoneal Carcinomatosis Diagnosis
Tumor Grade
“Tumor grade” describes how much the tumor appears like normal tissue when examined under a microscope.
The tumor grade helps physicians predict how quickly the cancer may grow.
G1: well-differentiated tumor cells
G2: moderately differentiated tumor cells
G3: poorly differentiated tumor cells
G4: undifferentiated tumor cells
Peritoneal Carcinomatosis Research, International
Review an extensive series of research articles by the world's most renowned specialists in this field:
Study of 523 Colorectal Peritoneal Carcinomatosis Cases: CRS and IPC
Source: Journal of Clinical Oncology,2010
Management of Peritoneal Carcinomatosis from Gastrointestinal Malignancies:
Research from 3rd International Symposium on Peritioneal Carcinomatosis, June 2008
Source: Prof Pompiliu Piso and Colleagues
Clinical Trials
Click here for a listing of research studies and clinical trials
Peritoneal Carcinomatosis Prognosis
Morbidity and Mortality: Study of HIPEC and CRS for Treatment of Peritoneal Carcinomatosis
Source: Annals of Surgery, Feb 2009, Dr David Morris, Dr Tristan Yan
CRS and HIPEC offer longterm survival for Peritoneal Carcinomatosis of disseminated Appendiceal tumor origin
Source: Dr Armando Sardi, Mercy Med Center, Journal of American College of Surgeons, Sept 2009
Peritoneal Carcinomatosis Prognosis following treatment with surgery and HIPEC
Source: Prof P Piso, 2009
Prognosis for Peritoneal Carcinomatosis following surgery and IP treatment at Mayo Clinic
Phase I Study for Patients with Peritoneal Carcinomatosis
Advances in Peritoneal Surface Oncology
Source: Dr S. González-Moreno
http://www.springer.com/west/home/medicine/oncology?SGWID=4-10073-22-112580385-0
Peritoneal Carcinomatosis :
“Appendiceal Carcinoma with Peritoneal Dissemination: Outcomes for the Best of the Best.”
Source: Annals of Surgical Oncology,2007, Dr Edward Levine, WFU
Peritoneal Adenomucinosis vs Peritoneal Mucinous Carcinomatosis
Peritoneal Carcinomatosis and Cox II expression
Peritoneal Carcinomatosis (multiple publications
Peritoneal Carcinomatosis: What Can We Do About It?
Source:ASCO 2004
Prognostic indicators for Peritoneal Carcinomatosis originating with gastrointestinal adenocarcinoma
Source: Dr Paul Sugarbaker, 2005
Prognosis for Peritoneal Carcinomatois originating with Appendix Cancer
Source: Dr Paul Sugarbaker, Washington Hospital Center
Peritoneal Carcinomatosis Prognosis following treatment with TPN administered at home
Source: Pub Med, per "Nutrition" 2006
Peritoneal Carcinomatosis Prognosis with HIPEC
Peritoneal Carcinomatosis Index Score
Peritoneal Carcinomatosis Index (PCI) Score
Source: European Journal of Surgical Oncology, 2003
Peritoneal Carcinomatosis Index Score: Peritoneal Carcinomatosis Prognosis
Source: Dr Paul H Sugarbaker, 2005
Peritoneal Carcinomatosis Gene Coding
MUC 2 Gene Coding for Peritoneal Carcinomatosis
REG 4 Gene Coding for Peritoneal Carcinomatosis
Peritoneal Carcinomatosis Treatment*
Here is an international listing of treatment specialists
Read the "Pal Profiles" of Peritoneal Carcinomatosis patients who are leading active lives following treatment!
Peritoneal Carcinomatois Clinical Trials Study
Source: NIH, Dr James Pingpank, Feb 2009
Treatment with CRS and Chemotherapy
Source: Annals of Surgical Oncology, 2009
CRS and HIPEC for the Treatment of Peritoneal Carcinomatosis
Source: Prof Pompiliu Piso, 3rd Annual Symposium, 2008
Peritoneal Carcinomatosis Trial
Source: NCI/NIH Dr James Pinkpank, April 2007
Dr Paul Sugarbaker: Evaluation with Perioperative Chemotherapy Agents
Source: The Oncologist, Dr P Sugarbaker, Feb 2005
Peritoneal Malignancies
Dr Paul Mansfield, Dr Laura Lambert: CRS and Perioperative Intraperitoneal Chemotherapy for Colorectal Carcinomatosis:
Source: Annals of Surgical Oncology. 2007, Lambert, Laura A. and Paul F. Mansfield.
See: http://www.annalssurgicaloncology.org/cgi/content/full/14/11/3037
Treatment with Cytoreduction and HIPEC Treatment (pdf)
Treatment with chemo hyperthermic peritoneal perfusion (CHPP)
Source: Pub Med 2009
Quality of life following Surgery and HIPEC
Dr David : Bartlett: UPMC Koch Cancer Center Treatment
Source: UPMC Koch Cancer Center, Dr David L Bartlett
Dr Armando Sardi: Surgical Treatment for Peritoneal Carcinomatosis, and Appendix Cancer with HIPEC
http://www.mdmercy.com/centerExcellence/cancer_services/surgical_oncology/clinical_peritoneal.html
Dr Edward Levine, Dr Perry Shen: Wake Forest University Treatment
Source: Wake Forest University, Dr Edward Levine, Dr Perry Shen
Dr Gilly: Peritoneal Carcinomatosis Treatment for Gastric Cancer
Source: Karger Digestive Diseases, 2004
Peritoneal Carcinomatosis Treatment with Surgery
Treatment with HIPEC
Peritoneal Carcinomatosis Research
Peritoneal Carcinomatosis Treatment with HIPEC
Belgium
Surgery and HIPEC in Ghent
HIPEC in Belgium (includes graphic illustrations)
Canada
CRS and HIPEC
Source: Universite de Montreal, Canada, 2009
Phase II Study
Source: University of Calgary, Canada, 2009, Dr Wally Temple
France
Treatment of Malignant Peritoneal Tumors
Source: Press Med, 2009, Prof FN Gilly, Prof O Glehen
Germany
Study with Tumor Honing Peptides
Source: Dept of Nuclear Medicine, Germany, 2009
Safety of Gastric Resection with Cytoreductive Surgery and HIPEC
Source: Annals of Surgical Oncology 2009, Prof P Piso
Peritonectomy, Surgery for the Treatment Peritoneal Carcinomatosis
Source: Dr H Muller
Holland/Nederland
HIPEC in Holland
Hyperthermia
Hyperthermia (includes graphic photos)
Source: Springerlink 2006
Peritoneal Carcinomatosis in Animals
Intestinal Mucinous Adenocarcinoma with Pseudomyxoma Peritonei in a Dog
Source: Journal of the American Animal Hospital Assoc, 2003
Mucinous Adenocarinoma with Peritoneal Carcinomatosis in a Lion
Source: Springerlink, 2007
Peritoneal Carcinomatosis OB/GYN
Intraoperative IPHC w/Cisplatin Treatment for Peritoneal Carcinomatosis of Ovarian Origin
Case study of Peritoneal Carcinomatosis and HPV
Source: Croatia Journal of Medicine, Oct 2008
Pseudomyxoma Peritonei
Click here to read specifically about Pseudomyxoma Peritonei
Appendix Cancer
Click here to read specifically about Appendix Cancer
Health Insurance Solutions
Health insurance, government benefits, COBRA
Caregiving
Are you a caregiver for a loved one diagnosed with Pseudomyxoma Peritonei syndrome?
We provide many helpful resources on our CAREGIVING page!
After Treatment is Completed; Now What?
Post Treatment Plan for Cancer Survivors
Source: Journey Forward
Mission Statement of the PMP Pals' Network
Here is our mission to serve patients and their families
